Showing results (1511-1520 of 1,879) with videos related to
Sort By:
Pageof 188
Immunotherapy|March 23, 2018
Nivolumab-induced synchronous occurrence of myositis and hypothyroidism in a patient with squamous cell lung cancerSonja Badovinac, Marta Korsic, Kamelija Zarkovic, et al.Immunotherapy|January 11, 2019
Tolerability of subcutaneous immunoglobulin 20%, Ig20Gly, in pediatric patients with primary immunodeficienciesKenneth Paris, Elie Haddad, Michael Borte, et al.Immunotherapy|December 5, 2018
A study of the clinical characteristics and prognosis of advanced mucosal and cutaneous melanoma in a Chinese populationYong Zhang, Xiaomin Fu, Yalong Qi, et al.Immunotherapy|December 20, 2018
Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanomaAhmad Tarhini, David McDermott, Apoorva Ambavane, et al.Immunotherapy|November 28, 2019
Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practicesVamsidhar Velcheti, Sheenu Chandwani, Xin Chen, et al.Immunotherapy|November 30, 2017
Modulation of antitumor immunity with histone deacetylase inhibitorsTyler R McCaw, Troy D Randall, Andres Forero, et al.Immunotherapy|November 30, 2017
Chimeric switch receptor: switching for improved adoptive T-cell therapy against cancersJohan Ck Tay, Shijun Zha, Shu WangImmunotherapy|December 21, 2017
Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic reviewOmar Abdel-RahmanImmunotherapy|December 21, 2017
PD-1/PD-L1 in diseaseNyanbol Kuol, Lily Stojanovska, Kulmira Nurgali, et al.Immunotherapy|December 21, 2017
Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumabTakanobu Jotatsu, Keishi Oda, Yudai Yamaguchi, et al.Pageof 188